Kaitlyn Bader, Senior Editor

October 6-12 was National Physician Assistant Week.

Kwatra presented the abrocitinib data at EADV 2023.

Lindsey Zubritsky, MD, FAAD, discusses the importance of providing accurate eczema care education throughout the month of October.

This week’s collection of the latest dermatologic studies covers understanding the role of the skin microbiome in AD treatment, management of human hair follicle microbiome by a synthetic odorant, efficacy of tralokinumab in AD treatment, and considerations in geriatric dermatopathology.

Dupilumab’s efficacy was sustained through the 260-week open-label study.

After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.

Prepare your patients with helpful resources during National Eczema Awareness Month.

Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.

ICYMI, this week we had articles about JNJ-2113 advancing in plaque psoriasis. and ulcerative colitis clinical development, finding balance during busy conference seasons, numerous late-breaking announcements from EADV, and more.

Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.

The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

November is Hyperhidrosis Awareness Month, and dermatology clinicians are gearing up for another month of raising awareness to improve patient outcomes.

The PC Project provides patients with access to the International PC Research Registry for clinical help with their rare and painful skin condition.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

AbbVie announced the 24- and 52-week data at EADV 2023.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Kyverna Therapeutics can now initiate its phase 1/2 open-label, multicenter study of KYV-101.

This week’s collection of the latest dermatologic studies covers the incidence of keratinocyte carcinomas, upadacitinib used to treat discoid lupus erythematosus, considerations about hair camouflage for Black women with alopecia, and parent perspectives of infants undergoing surgical treatment for congenital melanocytic nevus.

A BLA is expected to be submitted by Q3 of 2024.

Prepare your patients with helpful resources during National Eczema Awareness Month.

ICYMI, this week we had articles about the beginning of National Eczema Awareness Month, OM1's new HS dataset, an interview with the founder and CEO of the Picking Me Foundation, and more.

The approval provides pediatric patients with a steroid-free topical therapy.

This year’s virtual atopic dermatitis conference takes place on Sunday, December 10, 2023.

In this week’s Pointers With Portela, the 208SkinDoc explains why individuals with certain careers have an increased risk of developing skin cancer.

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

The addition of an HS dataset adds approximately 26,000 new patient records.